Skip to main content

Advertisement

SpringerLink
Log in

Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

Polypoidal choroidal vasculopathy (PCV) is considered to be a good indication for photodynamic therapy (PDT). We evaluated pre-PDT factors predicting better visual acuity (VA) 1 year after PDT in patients with PCV.

Methods

We evaluated 181 eyes of 181 patients who underwent PDT and were followed up for 1 year. Additional treatments, if needed, were given every 3 months, with a maximum of four PDT sessions, for up to 9 months. We compared best-corrected VA (BCVA) 1 year after PDT with that before PDT. Pre-PDT factors favoring better BCVA 1 year after PDT were evaluated using stepwise multiple regression analysis.

Results

Mean BCVA improved from 0.29 ± 0.15 before PDT to 0.43 ± 0.32 1 year after PDT (p < 0.001). BCVA improved in 55 eyes (30.4%), and was maintained in 110 (60.8%). Pre-PDT factors predicting better BCVA at 1 year were better initial BCVA (β = 0.271, p < 0.001) within our eligibility criteria up to 0.6, a relatively small diameter of a network of vessels plus polypoidal lesions on indocyanine green angiography (β = 0.249, p < 0.001), and the absence of a polypoidal lesion under the fovea (β = 0.175, p = 0.011).

Conclusion

Better BCVA can be expected 1 year after PDT in eyes with PCV showing better initial BCVA, relatively small lesions on indocyanine green angiography, and no subfoveal polypoidal lesion before PDT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B (1990) Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10:1–8

    Article  CAS  PubMed  Google Scholar 

  2. Lee SC, Seong YS, Kim SS, Koh HJ, Kwon OW (2004) Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula. Ophthalmologica 218:193–201

    Article  CAS  PubMed  Google Scholar 

  3. Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, Wong TH (2004) Photodynamic therapy with verteporfin for symptomatic polypoidal vasculopathy: one-year results of prospective case series. Ophthalmology 111:1576–1584

    Article  PubMed  Google Scholar 

  4. Akaza E, Yuzawa M, Matsumoto Y, Kashiwakura S, Fujita K, Mori R (2007) Role of photodynamic therapy in polypoidal choroidal vasculopathy. Jpn J Ophthalmol 51:270–277

    Article  PubMed  Google Scholar 

  5. Silva RM, Figueira J, Cachulo ML, Duarte L, Faria de Abreu JR, Cunha-Vaz JG (2005) Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 243:973–979

    Article  CAS  PubMed  Google Scholar 

  6. Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, Ikuno Y, Tano Y (2008) One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 115:141–146

    Article  PubMed  Google Scholar 

  7. Spaide RF, Donsoff I, Lam DL, Yannuzzi LA, Jampol LM, Slakter J, Sorenson J, Freund KB (2002) Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 22:529–535

    Article  PubMed  Google Scholar 

  8. Otani A, Sasahara M, Yodoi Y, Aikawa H, Tamura H, Tsujikawa A, Yoshimura N (2007) Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 144:7–14

    Article  CAS  PubMed  Google Scholar 

  9. Akaza E, Mori R, Yuzawa M (2008) Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina 28:717–722

    Article  PubMed  Google Scholar 

  10. Wakabayashi T, Gomi F, Sawa M, Tsujikawa M, Tano Y (2008) Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol 92:936–940

    Article  CAS  PubMed  Google Scholar 

  11. Kurashige Y, Otani A, Sasahara M, Yodoi Y, Tamura H, Tsujikawa A, Yoshimura N (2008) Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 146:513–519

    Article  PubMed  Google Scholar 

  12. Tano Y, Ophthalmic PDT Study Group (2008) Guidelines for PDT in Japan. Ophthalmology 115:585–585.e6

    Article  PubMed  Google Scholar 

  13. Ojima Y, Tsujikawa A, Otani A, Hirami Y, Aikawa H, Yoshimura N (2006) Recurrent bleeding after photodynamic therapy in polypoidal choroidal vasculopathy. Am J Ophthalmol 141:958–960

    Article  PubMed  Google Scholar 

  14. Hirami Y, Tsujikawa A, Otani A, Yodoi Y, Aikawa H, Mandai M, Yoshimura N (2007) Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina 27:335–341

    Article  PubMed  Google Scholar 

  15. Tsujikawa A, Hirami Y, Nakanishi H, Ojima Y, Aikawa H, Tamura H, Otani A, Yoshimura N (2007) Retinal pigment epithelial tear in polypoidal choroidal vasculopathy. Retina 27:832–838

    Article  PubMed  Google Scholar 

  16. Yodoi Y, Tsujikawa A, Otani A, Aikawa H, Yoshimura N (2008) Chorioretinal anastomosis after photodynamic therapy for polypoidal choroidal vasculopathy: CRA after PDT for PCV. Int Ophthalmol 28:297–299

    Article  PubMed  Google Scholar 

  17. Silva RM, Cachulo ML, Figueira J, de Abreu JR, Cunha-Vaz JG (2007) Chorioretinal anastomosis and photodynamic therapy: a two-year follow-up study. Graefes Arch Clin Exp Ophthalmol 245:1131–1139

    Article  CAS  PubMed  Google Scholar 

  18. Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, Tano Y (2008) Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 92:70–73

    Article  CAS  PubMed  Google Scholar 

  19. Lai TY, Chan WM, Liu DT, Luk FO, Lam DS (2008) Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 92:661–666

    Article  CAS  PubMed  Google Scholar 

  20. Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, Garcia-Feijoo J, Leila M, Garcia-Sanchez J (2008) Short-term anatomic effect of ranibizumab for polypoidal choroidal vasculopathy. Eur J Ophthalmol 18:645–648

    CAS  PubMed  Google Scholar 

  21. Kokame GT, Yeung L, Lai JC (2010) Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: an Interim 6-month report. Br J Ophthalmol 94(3):297–301, doi: 10.1136/bjo.2008.150029

    Article  PubMed  Google Scholar 

  22. Uyama M, Wada M, Nagai Y, Matsubara T, Matsunaga H, Fukushima I, Takahashi K, Matsumura M (2002) Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol 133:639–648

    Article  PubMed  Google Scholar 

  23. Prakash M, Han DP (2006) Recurrent bullous retinal detachments from photodynamic therapy for idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol 142:1079–1081

    Article  PubMed  Google Scholar 

  24. Saito M, Iida T, Nagayama D (2008) Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment. Br J Ophthalmol 92:1642–1647

    Article  CAS  PubMed  Google Scholar 

  25. Yoon JS, Lee J, Lee SC, Koh HJ, Kim SS, Kwon OW (2007) Polypoidal choroidal vasculopathy in Korean patients with large submacular hemorrhage. Yonsei Med J 48:225–232

    Article  PubMed  Google Scholar 

  26. Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS (2006) Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 141:456–462

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was funded in part by the Research Committee on Chorioretinal Degenerations and Optic Atrophy, The Ministry of Health and Welfare of Japan (Mitsuko Yuzawa).

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Nihon University, School of Medicine, Surugadai Nihon University Hospital, 1-8-13 Surugadai, Kanda, Chiyoda-ku, Tokyo, 101-8309, Japan

    Ryusaburo Mori, Mitsuko Yuzawa, Zeon Lee, Miho Haruyama & Eriko Akaza

Authors
  1. Ryusaburo Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitsuko Yuzawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zeon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miho Haruyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eriko Akaza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitsuko Yuzawa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mori, R., Yuzawa, M., Lee, Z. et al. Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 248, 1233–1239 (2010). https://doi.org/10.1007/s00417-010-1365-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-010-1365-2

Keywords

Search

Navigation